Q BioMed Recent News Positive Reaction
Summary
- Strontium89 Agreement.
- Orphan Drug-Liver Cancer (Utroside-B).
- Additional Patents Canada & Japan (Utroside-B-Liver Cancer).
#biotech #cellularmedicine #cancer
(OTCQB:OTCPK:QBIO) Closed @ $1.53 up from $0.93 1/26 65%
Recent News (1/26-2/1/21) may have been the result.
Today Early it's retracing some, could be profits.
Q BioMed Expands Strontium89 Reach Through Agreement with UroGPO, the Largest Group Purchasing Organization for Independent Urology Clinics in the US
NEW YORK, Feb. 1, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today that it has been awarded a contract with UroGPO, the largest Group Purchasing Organization for urology private practice clinics in the US, whose members represent 650 urology group practices and 167 ambulatory surgery centers with more than 3,400 urologists.
Through the partnership, UroGPO will support the establishment of Strontium89 (Strontium Chloride Sr-89 Injection, USP) as an added radionuclide therapeutic choice. Strontium89 will be offered to UroGPO urology offices that treat patients with painful bone metastases from prostate and other urological cancers. Studies indicate prostate cancer has the highest risk of bone metastasis, with 8 out of 10 metastatic cases spreading to bone.
In the Strontium89 pivotal trial, as many as 79% of patients had pain relief with Strontium89, and twice as many patients treated with Strontium89 had no pain for 3 months compared with placebo. Further, new pain sites were less frequent in patients treated with Strontium891,2. Strontium89 is administered once every 3 months via injection, and patients can be re-treated if needed. Please see Important Safety Information below.
https://finance.yahoo.com/.../q-biomed-expands...
Q BioMed's Uttroside-B Receives U.S. FDA Orphan Drug Designation in the Treatment of Liver Cancer
NEW YORK, Jan. 27, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), announced today that the U.S. Food and Drug Administration's Office of Orphan Products Development has granted Orphan Drug Designation to Uttroside-B, a small molecule chemotherapeutic for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer. In preclinical studies, Uttroside-B was up to 10-times more potent against HCC cells than Sorafinib, the standard of care drug at the time.
As an Orphan Drug, Uttroside-B may benefit from a seven-year market exclusively following marketing approval, grant funding for clinical trials that contribute to marketing approval, protocol assistance, and tax credits. Preclinical testing is now underway to support an FDA Investigational New Drug (IND) application expected this year.
Q BioMed has the exclusive rights to the technology through an agreement with the Rajiv Gandhi Centre for Biotechnology, an autonomous Institute under the Department of Biotechnology, Government of India and the Oklahoma Medical Research Foundation.
Q BioMed's Uttroside-B Receives U.S. FDA Orphan Drug Designation in the Treatment of Liver Cancer
Q BioMed's Uttroside-B Receives Additional Patent Coverage in Canada and Japan
NEW YORK, Jan. 26, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), announces that it has received additional notices of patent allowances from both Canada and Japan for its Uttroside-B molecule intended to treat liver cancer. The patent titled "Uttroside-B and Derivatives Thereof as Therapeutics for Hepatocellular Carcinoma" is a Method Of Use patent that covers the use of Uttroside-B for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer. International and additional U.S. claims are currently under prosecution for the technology which addresses a severe unmet need for a safe and effective drug to treat HCC.
Q BioMed's Uttroside-B Receives Additional Patent Coverage in Canada and Japan
Disclaimer: All Micro/Small Cap Company(ies) profile(S) are/have been compiled by Small Cap Solutions, LLC based on information believed to be true and gathered either from client companies and/or third party(‘s)/web sites. These profiles are not guaranteed, neither implied, nor in writing, as to the accuracy and completeness of content, and has been prepared for information purposes only. As such, this profile may contain forward reaching statements, as defined in the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from the statements either expressed or implied herein.
Prospective investors are advised to review the Company’s periodic filings with the Securities and Exchange Commission or at yahoofinance.com otcmarkets.com Small Cap Solutions, LLC has received cash from a 3rd Parties for investor relations services rendered.
Small Cap Solutions, LLC and/or its Principal/Employees are not registered Broker(S)/Broker Dealer(S) with FINRA or the SEC. Small Cap Solutions, LLC does not make any buy/sell recommendations at any time, but may state their opinion on companies, etc. That is not meant to be a recommendation. All information disseminated by Small Cap Solutions, LLC is believed to be true and public.
Additional inquiries available by email to robkreh@smallcapsolutions.com or by mail to 303 Joppa Crossing Ct. (Suite#1) Joppa, Md. 21085. To unsubscribe to this mailing list, please reply "unsubscribe" to this message.
Analyst's Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.